pat1

Arecaidine hydrochloride may have carcinogenesis.

PAT1inh-B01 hydrochloride is a selective SLC26A6 inhibitor. It inhibits the anion exchange mediated by PAT1 (Cl-/HCO3- exchanger) with an IC50 of 350 nM. This compound blocks fluid absorption in the small intestine and can be used for research into diseases related to insufficient intestinal secretion.

PAT1inh-B01, a selective SLC26A6 inhibitor, impedes PAT1 (a Cl-/HCO3- exchanger) activity, with an IC50 of 350 nM, effectively inhibiting anion exchange. It also obstructs fluid absorption in the small intestine and is utilized in the study of small intestinal hyposecretory disorders [1].

PAT1inh-A0030 is a selective inhibitor of PAT1 (SLC26A6) with an IC 50 value of 1.0 μM. It inhibits fluid absorption in the ileum of wild-type and cystic fibrosis (CF) mice (CftrdelF508/delF508) in a closed-loop model of intestinal fluid absorption and can be used in the study of intestinal diseases related to CF [1].

PAT-1251 is an inhibitor of LOXL2 with IC50s of 10, 0.12, and 0.16 μM for the mouse, rat, and dog and can be used in studies about fibrotic diseases.

PAT-1251 Hydrochloride is a potent, selective, and oral inhibitor of lysyl oxidase-like 2 (LOXL2), targeting hLOXL2 and hLOXL3 with IC50 values of 0.71 and 1.17 μM, respectively.

Arecaidine hydrobromide is the salt form of Arecaidine, a pyridine alkaloid with potent GABA uptake inhibitory properties that acts as a substrate for H+-coupled amino acid transporter protein 1 (PAT1, SLC36A1) to competitively inhibit the uptake of L-proline.